Strides Acrolab received FDA approval for the Oxaliplatin injection
Strides Arcolab’s subsidiary Onco Therapies has received final approval from the US health regulator for its generic version of Oxaliplatin injection used for treating cancer.
Mumbai, August 8, 2012: Onco Therapies Ltd, a subsidiary of Strides Acrolab today said that the company has received US FDA approval for the Oxaliplatin injection. The US market for the generic version of the Oxaliplatin injection is approximately worth US$ 1.5 billion.
It may be noted here that Oxaliplatin is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for launch. In fact, Oxaliplatin is a chemotherapy drug which used to treat advanced cancer of the colon and rectum. It is used in combination with the other medications to slow or stop the growth of cancer cells.
Strides Acrolab with 14 manufacturing facilities across six countries has a presence in more than 75 countries. With its 350-scientist strong global R&D centre in Bangalore, the company has already made its name in the wide range of IP-led niche pharmaceutical products with a huge focus on sterile injectables.